2-(3,4-Dimethoxyphenyl)-N-(4-methoxyphenyl)-1-propyl-1H-benzo[d]imidazole-5carboxamide was synthesized by the 'one-pot' reductive cyclization of N-(4-methoxyphenyl)-3nitro-4-(propylamino)benzamide with 3,4-dimethoxybenzaldehyde, using sodium dithionite as a reductive cyclizing agent using DMSO as a solvent. The structure of newly synthesized compound was elucidated based on IR, 1 H-NMR, 13 C-NMR, and LC-MS data.
Introduction
Benzimidazole is important class of heterocyclic compounds having an imidazole ring, which represents one of the most biologically active classes of compounds, possessing a wide spectrum of activities that are well documented in literature [1] . Due to its special spectral features and electron rich environment, benzimidazole containing drugs bind to a variety of therapeutic targets. Substituted benzimidazole derivatives are associated with various types of pharmacokinetic and pharmacodynamics properties. These properties of the benzimidazole derivatives is due to their affinity towards the variety of enzymes and the protein receptors. Benzimidazole derivatives act as proton pump inhibitors by accumulating in the parietal cell and binding directly to the enzyme, which results in inhibition of gastric acid secretion [2] . Benzimidazole derivatives show their antibacterial activity by inhibiting the bacterial nucleic acid and proteins synthesis. Benzimidazole derivatives show their antifungal activity by blocking the polymerization of αand β-tubulin subunits. The benzimidazole disrupt microtubule function in eukaryotic organisms such as fungi, protozoa, and helminths. The antibacterial and antifungal activity of benzimidazole derivatives is due to its close relationship with structure of purines [3] . Thus, benzimidazole derivatives have found a very strong application in the medicine filed. The synthesis and application of benzimidazole and its derivatives is discussed in several articles [4, 5] . Optimization of substituents around the benzimidazole nucleus has resulted in many drugs like Albendazole, Mebendazole, Triclabendazole, Fenbendazole, Oxfendazole, Thiabendazole, Omeprazole, Lansoprazole, and Pantoprazole [6] . Benzimidazole and its derivatives have associated with diverse biological activities such as anti-microbial [7] [8] [9] , anti-inflammatory and analgesic [10] , anti-tubercular [11] , anti-oxidant [12] , anti-fungal [13] , anti-convulsant/anti-diabetic [14] , and anti-viral [15] . Substituted benzimidazole derivatives have found commercial applications in diverse human therapeutics, especially for treating various types of cancers [16] [17] [18] [19] [20] . Carboxamide compounds have diversified applications in medicinal chemistry as an important pharmacophore found in many marketed drug molecules [21] . Carboxamide's potential as a pharmacophore is due to its capability as an H-bond donor and acceptor [22, 23] . It is an active unit in many drug molecules due to its property to bind with protein molecules [24] . Various heterocyclic moieties with amide functionality have displayed various potent biological activities as anti-cancer [25, 26] , anti-convulsant [27] , anti-tubercular [28] , anti-oxidant [29] and anti-inflammatory [30] activities. 'One-pot' synthesis of benzimidazole has gained much attraction in synthetic organic chemistry as it reduces the number of steps involved and the reaction time, and increases the yield of the product [31] . 'One-pot' reductive cyclization was found to be highly efficient using sodium dithionite as reductive cyclizing agent compared to other reagents [32] [33] [34] [35] . Thus, in this paper we describe the efficient synthesis and characterization (by IR, 1 H-NMR, 13 C-NMR, and LC-MS spectral data) of new benzimidazole coupled carboxamide.
Results and Discussion
Synthesis of 2-(3,4-dimethoxyphenyl)-N-(4-methoxyphenyl)-1-propyl-1H-benzo[d]imidazole-5carboxamide 3 is depicted in Scheme 1. Initially, N-(4-methoxyphenyl)-3-nitro-4-(propylamino)benzamide 1 was obtained by the simple acid amine coupling of p-Anisidine and 3-propylamino-2-nitro-benzoic acid. Further, product 3 was obtained by heating the compound 1 with 3,4-dimethoxybenzaldehyde 2 and sodium dithionite (Na 2 S 2 O 4 ) as a reducing agent in dimethyl sulphoxide (DMSO) medium at 90 • C for about 3 h. The obtained product 3 was isolated by means of simple water workup and purified by recrystallization process in a DMF (dimethylformamide) solvent.
Molbank2019, 2019, x 2 of 5 derivatives have found commercial applications in diverse human therapeutics, especially for treating various types of cancers [16] [17] [18] [19] [20] . Carboxamide compounds have diversified applications in medicinal chemistry as an important pharmacophore found in many marketed drug molecules [21] . Carboxamide's potential as a pharmacophore is due to its capability as an H-bond donor and acceptor [22, 23] . It is an active unit in many drug molecules due to its property to bind with protein molecules [24] . Various heterocyclic moieties with amide functionality have displayed various potent biological activities as anti-cancer [25, 26] , anti-convulsant [27] , anti-tubercular [28] , anti-oxidant [29] and anti-inflammatory [30] activities. 'One-pot' synthesis of benzimidazole has gained much attraction in synthetic organic chemistry as it reduces the number of steps involved and the reaction time, and increases the yield of the product [31] . 'One-pot' reductive cyclization was found to be highly efficient using sodium dithionite as reductive cyclizing agent compared to other reagents [32] [33] [34] [35] . Thus, in this paper we describe the efficient synthesis and characterization (by IR, 1 H-NMR, 13 C-NMR, and LC-MS spectral data) of new benzimidazole coupled carboxamide. The structure of the compound 3 was confirmed by IR, 1 H-NMR, 13 C-NMR, and LC-MS spectral data. The 1 H-NMR spectrum of compound 3 showed a presence of a down-field singlet at δ 10.263 for its -NH proton, indicating the presence of a carboxamide group. The proton ortho to the carbonyl group of amides appeared as a singlet at δ 8.350 ppm and the remaining two protons of the benzimidazole ring appeared as a multiplets in the region of δ 8.028-8.094 ppm. The protons meta and ortho to the methoxy group of the amide phenyl ring appeared as two distinct doublets centered at 7.6865 and 6.9195 ppm with J = 9.2 Hz and 8.4 Hz, respectively. The three protons of the aryl ring at the 2nd position of benzimidazole appeared at 7.229-7.251 and 7.433-7.449 ppm. The presence of triplet at δ 4.410 ppm (J = 7.2 Hz) for its N-CH2 protons, a multiplets at δ 1.735-1.790 ppm for the central -CH2 protons, and another triplet at δ 0.768-0.804 ppm (J = 7.2 Hz) for the -CH3 proton confirms the presence of propyl substituent at the 1st position of benzimidazole. Furthermore, its spectrum showed the presence of three distinct singlet at δ 3.726, 3.838, and 3.865 ppm for their three methoxy protons attached to two phenyl rings. In 13 The structure of the compound 3 was confirmed by IR, 1 H-NMR, 13 C-NMR, and LC-MS spectral data. The 1 H-NMR spectrum of compound 3 showed a presence of a down-field singlet at δ 10.263 for its -NH proton, indicating the presence of a carboxamide group. The proton ortho to the carbonyl group of amides appeared as a singlet at δ 8.350 ppm and the remaining two protons of the benzimidazole ring appeared as a multiplets in the region of δ 8.028-8.094 ppm. The protons meta and ortho to the methoxy group of the amide phenyl ring appeared as two distinct doublets centered at 7.6865 and 6.9195 ppm with J = 9.2 Hz and 8.4 Hz, respectively. The three protons of the aryl ring at the 2nd position of benzimidazole appeared at 7.229-7.251 and 7.433-7.449 ppm. The presence of triplet at δ 4.410 ppm (J = 7.2 Hz) for its N-CH 2 protons, a multiplets at δ 1.735-1.790 ppm for the central -CH 2 protons, and another triplet at δ 0.768-0.804 ppm (J = 7.2 Hz) for the -CH 3 proton confirms the presence of propyl substituent at the 1st position of benzimidazole. Furthermore, its spectrum showed the presence of three distinct singlet at δ 3.726, 3.838, and 3.865 ppm for their three methoxy protons attached to two phenyl rings. In 13 C-NMR spectrum of 3, -C=O carbon of -CONH (carboxamide group) appeared at δ 165.116 ppm, which confirms the presence of the amide carbonyl group. Further, it shows signals for the aromatic carbons at δ 156. 039, 151.758, 149.316, 136.640, 132.699, 131.298, 124.050, 123.165, 122.523, 116.753, 114.204, 113.192, 112 .414, and 112.278 ppm, which confirms the presence of three aromatic rings in compound 3. In its 13 C-NMR spectrum, it shows signals at δ 46.947 ppm, δ 22.810 ppm, and δ 11.251 ppm for the N-CH 2 , CH 2 , and CH 3 carbon atoms of the propyl chain, respectively. Further, -OCH 3 carbons appeared at δ 56.239 and 55.645 ppm, which confirms the presence of three methoxy groups attached to the aromatic ring. Compound 3 was further confirmed by its mass spectra; MS (m/z): 446.1806 [M + H] + corresponding to its molecular weight.
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Materials and Methods

Instruments
All the chemicals used were acquired from Spectrochem (Bangalore, India) and Sigma-Aldrich Company (Bangalore, India). All the solvents and reagents used were dried by standard methods wherever required. The 1 H-NMR spectra were recorded on an Agilent-NMR (400 MHz, Agilent, Santa Clara, CA, USA) spectrometer and 13 C-NMR spectra was recorded on an Agilent-NMR spectrometer (100 MHz, Santa Clara, CA, USA) with DMSO-d 6 as the solvent. Chemical shifts were reported in δ ppm (parts per million) values; multiplicities are indicated by s (singlet), d (doublet), t (triplet), and m (multiplets). Coupling constants (J) were reported in hertz (Hz). The mass spectroscopy of the synthesized compounds was performed on a mass spectrophotometer (MODEL-WATERS, SYNAPT G2 APCI mode, Milford, MA, USA). The progress of the reaction was monitored by thin layer chromatography (TLC) using precoated silica plates 60 F254 aluminium sheets and visualization was done by UV light at 254 nm (UV lamp light 254/365 nm). The melting point was determined by an open capillary method and are uncorrected. The IR spectra were recorded on a Bruker FT-IR spectrophotometer (Bruker, Billerica, MA, USA).
Synthetic Procedures
The synthetic procedure was optimized based on the trial experiments and the yields were not optimized. The starting material N-(4-methoxyphenyl)-3-nitro-4-(propylamino)benzamide 1 was prepared by coupling of 3-nitro-4-(propylamino)benzoic acid with p-Anisidine using N,N,N',N'-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) as coupling agent in the presence of N-Methylmorpholine (NMM) base in DMF medium. To a solution of N-(4-methoxyphenyl)-3-nitro-4-(propylamino)benzamide 1 (1 eq) in DMSO, 3,4-dimethoxybenzaldehyde (1 eq) 2 and sodium dithionite were added (3 eq). The reaction mass was stirred at 90 • C for 3 h. Completion of the reaction was monitored by thin layer chromatography (TLC) (Hexane:Ethyl acetate; 7:3 v/v). After completion of reaction, the reaction mass was poured into crushed ice. The solid product obtained was filtered, washed with cold water, and dried. Then, compound 3 was recrystallized using dimethylformamide (DMF) solvent.
Molecular formula: C 26 
